Efficacy and Safety of a Fixed-Dose Combination of Vildagliptin and Pioglitazone in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Comparative, Phase III Study

Background Type 2 diabetes mellitus (T2DM) arises due to a range of pathological abnormalities, necessitating a combination therapy to achieve optimal glycemic control. Vildagliptin, an effective and selective DPP-4 inhibitor, and pioglitazone, an insulin sensitizer, offer distinct mechanisms of act...

Descripción completa

Detalles Bibliográficos
Autores principales: Erande, Suhas, Mukhopadhyay, Jotideb, Dange, Amol, Deogaonkar, Anushka, Birla, Ashish, Doshi, Chetan, Revankar, Santosh, B, Sridhar S, Kumar, Neeraj, Kadam, Pramod V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547078/
https://www.ncbi.nlm.nih.gov/pubmed/37795066
http://dx.doi.org/10.7759/cureus.44548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547078/
https://www.ncbi.nlm.nih.gov/pubmed/37795066
http://dx.doi.org/10.7759/cureus.44548

Ejemplares similares